Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.80 [0.67, 0.96] | | < 1 | | 0% | 2 studies (2/-) | 99.2 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 0.53 [0.45, 0.64] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 7.07 [4.06, 12.33] | | > 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
TRAE (any grade) | 0.65 [0.46, 0.93] | | < 1 | | 0% | 2 studies (2/-) | 99.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.49 [0.33, 0.71] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 1.23 [0.65, 2.35] | | < 1 | | 1% | 2 studies (2/-) | 26.2 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 2.06 [0.87, 4.87] | | < 1 | | 0% | 2 studies (2/-) | 5.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Alopecia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Anaemia TRAE (grade 3-4) | 0.08 [0.01, 0.43] | | < 1 | | 0% | 2 studies (2/-) | 99.8 % | some concern | not evaluable | moderate | non important | - |
Arthralgia TRAE (grade 3-4) | 0.96 [0.13, 6.84] | | < 1 | | 0% | 2 studies (2/-) | 51.7 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.96 [0.13, 6.84] | | < 1 | | 0% | 2 studies (2/-) | 51.7 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 1.66 [0.25, 11.00] | | < 1 | | 0% | 2 studies (2/-) | 30.0 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.68 [0.10, 4.48] | | < 1 | | 33% | 2 studies (2/-) | 65.4 % | some concern | not evaluable | moderate | non important | - |
Dry skin TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 0.23 [0.08, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
Hepatitis TRAE (grade 3-4) | 2.26 [0.20, 25.79] | | < 1 | | 0% | 2 studies (2/-) | 25.8 % | some concern | not evaluable | moderate | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Hypophysitis TRAE (grade 3-4) | 1.43 [0.11, 18.64] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.92 [0.17, 21.29] | | < 1 | | 0% | 2 studies (2/-) | 29.9 % | some concern | not evaluable | moderate | non important | - |
Myalgia TRAE (grade 3-4) | 1.21 [0.17, 8.64] | | < 1 | | 0% | 2 studies (2/-) | 42.5 % | some concern | not evaluable | moderate | non important | - |
Nausea TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
Neutropenia TRAE (grade 3-4) | 0.08 [0.01, 0.60] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
Pancreatitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 3.58 [0.38, 34.02] | | < 1 | | 0% | 2 studies (2/-) | 13.5 % | some concern | not evaluable | moderate | non important | - |
Pruritus TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
Uveitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
Vomiting TRAE (grade 3-4) | 0.24 [0.05, 1.12] | | < 1 | | 0% | 2 studies (2/-) | 96.5 % | some concern | not evaluable | moderate | non important | - |